Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R W Wilkinson

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The Journal of Cell Biology|July 1, 1994
The bovine desmocollin family: a new gene and expression patterns reflecting epithelial cell proliferation and differentiationP K Legan, K K Yue, M A Chidgey, et al.
British Journal of Cancer|October 12, 2000
A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1R W Wilkinson, E L Ross, A E Lee-MacAry, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2001
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumorsR W Wilkinson, E L Ross, R Poulsom, et al.
Journal of Immunological Methods|May 4, 2001
Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodideA E Lee-MacAry, E L Ross, D Davies, et al.
Journal of Theoretical Biology|October 4, 2017
A mathematical model of antibody-dependent cellular cytotoxicity (ADCC)F Hoffman, D Gavaghan, J Osborne, et al.
British Journal of Cancer|February 21, 2012
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsS V Holt, A Logié, R Odedra, et al.
Cancer Immunology, Immunotherapy : CII|April 15, 1999
Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigenL M Stewart, S Young, G Watson, et al.
Carcinogenesis|June 20, 2006
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancerR A Goodlad, A J Ryan, S R Wedge, et al.
Cancer Biomarkers : Section a of Disease Markers|May 2, 2009
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarkerM Hägg Olofsson, J Cummings, W Fayad, et al.
International Journal of Colorectal Disease|May 3, 2005
Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I studyA P Zbar, H Thomas, R W Wilkinson, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Journal of Cell Biology|July 1, 1994
The bovine desmocollin family: a new gene and expression patterns reflecting epithelial cell proliferation and differentiationP K Legan, K K Yue, M A Chidgey, et al.
British Journal of Cancer|October 12, 2000
A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1R W Wilkinson, E L Ross, A E Lee-MacAry, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2001
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumorsR W Wilkinson, E L Ross, R Poulsom, et al.
Journal of Immunological Methods|May 4, 2001
Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodideA E Lee-MacAry, E L Ross, D Davies, et al.
Journal of Theoretical Biology|October 4, 2017
A mathematical model of antibody-dependent cellular cytotoxicity (ADCC)F Hoffman, D Gavaghan, J Osborne, et al.
British Journal of Cancer|February 21, 2012
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsS V Holt, A Logié, R Odedra, et al.
Cancer Immunology, Immunotherapy : CII|April 15, 1999
Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigenL M Stewart, S Young, G Watson, et al.
Carcinogenesis|June 20, 2006
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancerR A Goodlad, A J Ryan, S R Wedge, et al.
Cancer Biomarkers : Section a of Disease Markers|May 2, 2009
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarkerM Hägg Olofsson, J Cummings, W Fayad, et al.
International Journal of Colorectal Disease|May 3, 2005
Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I studyA P Zbar, H Thomas, R W Wilkinson, et al.
Pageof 3